Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Agenus Inc (AGEN)

$3.71 0.00 (0.13%)

17:17 EST AGEN Stock Quote Delayed 15 Minutes

Volume:

Previous Close $3.71

Market Cap 385.32M

PE Ratio -2.34

EPS -1.58

Volume (Avg. Vol.) 507,400

Day's Range 3.68 - 3.76

52-Week Range 2.13 - 4.57

Dividend & Yield N/A (N/A)

AGEN Stock Predictions, Articles, and Agenus Inc News

From InvestorPlace
From the Web

4 Market-Beating Sector ETFs and Stocks

By Zacks Investment Research Feb 28, 2018

A few sectors have easily survived the market rout and are crushing the broad market this month. Compare Brokers...

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

From Zacks Investment Research Jan 9, 2020

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

From Zacks Investment Research Jan 8, 2020

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

Innate Pharma's Filing for Leukemia Drug Accepted in Europe

From Zacks Investment Research Jan 3, 2020

The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.

Pulmatrix Surges on License Agreement With Johnson & Johnson

From Zacks Investment Research Jan 3, 2020

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

Amicus Progresses on Pipeline Development Amid Competition

From Zacks Investment Research Jan 3, 2020

Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

From Zacks Investment Research Jan 3, 2020

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

C

Hold